The Etiology of Acute Febrile Illness Requiring Hospitalization

NCT ID: NCT02763462

Last Updated: 2023-05-03

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1492 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-07-31

Study Completion Date

2017-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is an observational cohort study of hospitalized patients with fever. This study will collect demographic data, history of illness, signs and symptoms, results of laboratory tests, clinical course, treatment and outcome. This study conducted at eight INA-RESPOND hospitals. Potential study patients will be any patients (both children and adults).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is an observational cohort to identify the etiologies of acute febrile illness (less than or equal to 2 weeks), which are thought to be endemic or novel in a certain area. Therefore, there are no hypotheses that require sample size calculation to be tested. It is expected that this study will enroll a minimum of 200 patients per site: approximately 100 adults and 100 pediatric cases. The final sample size is therefore estimated to be 1600.

Primary Objective:

To identify the etiology of acute febrile illness cases and evaluate clinical manifestations and outcomes.

Secondary Objectives:

1. To provide clinical data that are essential for improving and/or developing clinical management and health policies.
2. To enhance research capacity and networking for infectious diseases in Indonesia by improving clinical research site capability in conducting research relevant to public health.
3. To establish a repository of biological specimens for future study, such as determining the etiology of undiagnosed fever and/or its pathogenicity and its public health importance.

This study will be conducted at all the INA-RESPOND hospitals (8 hospitals):

* Dr. Cipto Mangunkusumo Hospital , Jakarta
* Penyakit Infeksi Prof. Dr. Sulianti Saroso Hospital, Jakarta
* Dr. Hasan Sadikin Hospital, Bandung
* Dr. Kariadi Hospital, Semarang
* Dr. Sardjito Hospital, Yogyakarta
* Dr. Soetomo Hospital, Surabaya
* Sanglah Hospital, Bali
* Dr. Wahidin Soedirohusodo Hospital, Makassar

The study will enroll eligible fever patients for a period of up to 1 year. Follow-up may be up until one year after last subject is enrolled. Stored samples will be investigated during the study and/or after study completion.

After enrollment, patients will be seen at 14-28 days and at 3 months post enrollment. Patients will be seen every 3 months (6, 9, and 12 months within a window period of +/- 14 days) until cured and no related symptoms persists or the one year time point is reached. The samples will be collected for storage at enrollment, the 14-28 day visit, at 3 months and every 3 months thereafter if not cured.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Febrile Illness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥1 year
* Acute febrile illness requiring hospitalization (fever defined as temperature recorded ≥38.0°C during the first 24 hour period of hospitalization).
* Hospitalized within the past 24 hours.
* Willing to allow storage of blood and other specimens for use in future studies of infectious diseases.

Exclusion Criteria

* Hospitalized within the past 3 months, not including current hospitalization for acute febrile illness.
* Inpatient transfer from another hospital.
* A known medical disorder or other circumstance, which in the opinion of the PI might make the participation of the individual unsafe or difficult.

Examples include, but not limited to: mental illness which could affect compliance with protocol, an anemic patient preventing blood draw.
Minimum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Health Research and Development, Ministry of Health Republic of Indonesia

OTHER

Sponsor Role collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role collaborator

Ina-Respond

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Prof. dr. M. Hussein Gasem, PhD, SpPD-KPTI

Role: PRINCIPAL_INVESTIGATOR

University of Diponegoro/ Dr. Kariadi hospital

Prof. Emiliana Tjitra, MSC, Ph.D

Role: PRINCIPAL_INVESTIGATOR

NIHRD, Indonesia

Dr. Bachti Alisjahbana, PhD, SpPD-KPTI

Role: PRINCIPAL_INVESTIGATOR

Univerversity of Padjajaran / Dr. Hasan Sadikin Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Udayana/Sanglah Hospital

Denpasar, Bali, Indonesia

Site Status

University of Diponegoro/ Dr. Kariadi Hospital

Semarang, Central Java, Indonesia

Site Status

University of Indonesia/ Dr. Cipto Mangunkusumo Hospital

Jakarta, DKI Jakarta, Indonesia

Site Status

Penyakit Infeksi Sulianti Saroso Hospital

Jakarta, DKI Jakarta, Indonesia

Site Status

University of Airlangga/ Dr. Soetomo Hospital

Surabaya, East Java, Indonesia

Site Status

University of Padjajaran/ Dr. Hasan Sadikin Hospital

Bandung, West Java, Indonesia

Site Status

University of Hassanudin/ Dr. Wahidin Sudirohusodo Hospital

Makassar, , Indonesia

Site Status

University of Gadjah Mada/ Dr. Sardjito Hospital

Yogyakarta, , Indonesia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Indonesia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U1111-1263-2248

Identifier Type: OTHER

Identifier Source: secondary_id

HHSN261200800001E

Identifier Type: OTHER

Identifier Source: secondary_id

HHSN261201500003I

Identifier Type: OTHER

Identifier Source: secondary_id

INA101

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Survey of COVID-19 Infection
NCT05706064 COMPLETED